Navigation Links
inVentiv Selling Solutions Selected to Provide Sales Team for Cephalon Inc.
Date:3/6/2008

es include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota. The company's European headquarters are located in Maisons-Alfort, France.

The company's proprietary products in the United States include: PROVIGIL(R) (modafinil) Tablets [C-IV], FENTORA(R) (fentanyl buccal tablet) [C-II], TRISENOX(R) (arsenic trioxide) injection, AMRIX(R) (cyclobenzaprine hydrochloride extended-release capsules), VIVITROL(R) (naltrexone for extended-release injectable suspension), GABITRIL(R) (tiagabine hydrochloride), NUVIGIL(TM) (armodafinil) Tablets [C-IV] and ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II]. The company also markets numerous products internationally. Full prescribing information on its U.S. products is available at http://www.cephalon.com or by calling 1-800-896-5855.

About inVentiv Health

inVentiv Health, Inc. (Nasdaq: VTIV) is an insights-driven global healthcare leader that provides dynamic solutions to deliver customer and patient success. inVentiv delivers its customized clinical, sales, marketing and communications solutions through its four core business segments: inVentiv Clinical, inVentiv Communications, inVentiv Commercial, and inVentiv Patient Outcomes. inVentiv Health's client roster is comprised of more than 325 leading pharmaceutical, biotech, life sciences and healthcare payor companies, including all top 20 global pharmaceutical manufacturers. For more information, visit http://www.inventivhealth.com.

This press release contains forward-looking st
'/>"/>

SOURCE inVentiv Health, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. inVentiv Health to Present at the 20th Annual Bear Stearns Healthcare Conference
2. inVentiv Health to Announce Third Quarter Results and Conduct Conference Call on Wednesday, November 7, 2007
3. inVentiv Health Launches Fourth Business Segment: inVentiv Patient Outcomes
4. inVentiv Health to Present at the 2007 Credit Suisse Healthcare Conference
5. inVentiv Health Creates Client Development and Integration Team
6. inVentiv Health Provides Updated Information on December 11th Investor Day
7. inVentiv Health to Announce Fourth Quarter and Full Year 2007 Results and Conduct Conference Call on Thursday, February 28th
8. inVentiv Health Ranked #17 by Training Magazine in its 2008 List of Top 125 Training Companies
9. inVentiv Health Reports Record Financial Results for Fourth Quarter and Full Year 2007
10. Federal Trade Commission Attempts To Suppress Best-Selling Authors First Amendment Rights
11. FTC Attacks Infomercial Marketer to Silence Best-Selling Authors Weight-Loss Tips
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2008)... Saturday, September 6, PARI,Respiratory Equipment...,s,Family as part of their "Breathe Easier" series...company that provides patients, such as COPD,suffe...at deliver needed,medications directly to the lung...affected by respiratory,diseases and those who car...
(Date:9/5/2008)...ht or obese at age 45 , , FRIDAY, Sept. ...adults will develop osteoarthritis of the knee by ...in middle age, a new study says. , A person,s ...his or her body-mass index (BMI) rose, according t...study. People who were of normal weight at age 18 ...
(Date:9/5/2008)...are enhanced by taking into account risk factors b...ding to research teams led by epidemiologists at T...r in two complementary papers appearing in the Sep...In the first study to focus on African-Americans, ...d exposure to certain risks. Based upon these find...
(Date:9/4/2008)...care Advantage (MA) plans will be paid an average ... what the same enrollee would have cost in the tra...ng to a new report from The Commonwealth Fund. Ev...by the Medicare Improvements for Patients and Prov...t beginning in 2010 had been fully in place in 20...
Breaking Medicine News(10 mins):Health News:PARI Respiratory Equipment Featured on Oxygen Network 2Health News:Almost Half of Adults Will Develop Knee Osteoarthritis by 85 2Health News:Creating lung cancer risk models for specific populations refines prediction 2Health News:Creating lung cancer risk models for specific populations refines prediction 3Health News:Extra payments to Medicare Advantage plans to total $8.5 billion in 2008 2
... and solvents can further lower fertility among in... these chemicals may worsen the effect of pre-exis...ty. The authors stress the findings should be trea... a selected population of infertile men, from a pr...
...ssociation(AMA) is spending a lot of drug-company ...om drug companies. The AMA says it makes sense to ...igned to inform drug makers about what is consider...re the myriad freebies, ranging from pens and note...
...er than massage as a treatment for chronic neck pa...apies when used over long periods.That's the concl...effectiveness of the complementary medicine techni...into special sites in the nervous system.// The st...
...s born to deaf parents and exposed mainly to sign ...ndicating that babbling serves as an important pre...tto, a professor in the departments of Psychologic...artmouth College in Hanover, New Hampshire believe...
Other Medicine News:
(Date:9/4/2008)... on Schedule with Two Abstracts Accepted for P...vember 2008, BRIDGEWATER, N.J., Sept. 4 /PRNewswi... pharmaceutical company focused on the treatment o...unced the appointment of,Peter L. Garrambone, Jr. ...mbone,s career includes more than 50 pharmaceutica...
(Date:9/3/2008).../- Simcere,Pharmaceutical G...plier of,branded generic pharmaceuticals and manuf...t Endu (also known as Endostar) in China,announce...udy., At the request of the SFDA, Simcere initiat...he safety and therapeutic efficacy of Endu, a modi...
(Date:9/3/2008)...onal Vascular Disease Awareness Month, CHARLOTTES...maceuticals,LLC, a clinical-stage drug-development...nt of unmet medical needs, announced today that it...ical trial of its lead drug,candidate trans sodium...881,on the clinicaltrials.gov Website, is investig...
(Date:9/3/2008)...Multaq(R) (dronedarone) decreased the risk of,stro...trial flutter already adequately trea... Sept. 3 /- The results of ...udy were presented today at,the clinical trial upd...congress 2008, in Munich, Germany. Previous result...
Breaking Medicine Technology:Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials 2Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 2Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 3Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 2Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 3Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 4Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 2Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 3Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 4Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 5Nationwide Survey Reveals Differing Physician and Patient Perceptions Regarding Impact of Ulcerative Colitis on Patients Lives 7826 1Nationwide Survey Reveals Differing Physician and Patient Perceptions Regarding Impact of Ulcerative Colitis on Patients Lives 7826 2Nationwide Survey Reveals Differing Physician and Patient Perceptions Regarding Impact of Ulcerative Colitis on Patients Lives 7826 3Nationwide Survey Reveals Differing Physician and Patient Perceptions Regarding Impact of Ulcerative Colitis on Patients Lives 7826 4Nationwide Survey Reveals Differing Physician and Patient Perceptions Regarding Impact of Ulcerative Colitis on Patients Lives 7826 5Nationwide Survey Reveals Differing Physician and Patient Perceptions Regarding Impact of Ulcerative Colitis on Patients Lives 7826 6Nationwide Survey Reveals Differing Physician and Patient Perceptions Regarding Impact of Ulcerative Colitis on Patients Lives 7826 7Nationwide Survey Reveals Differing Physician and Patient Perceptions Regarding Impact of Ulcerative Colitis on Patients Lives 7826 8Submission of Marketing Authorisation Application for Dapoxetine in Europe 7823 1Submission of Marketing Authorisation Application for Dapoxetine in Europe 7823 2Katie Lee Joel to Conduct Free Hands On Holiday Cooking Demonstration for Local Patients With Chronic Kidney Disease 2103 1Katie Lee Joel to Conduct Free Hands On Holiday Cooking Demonstration for Local Patients With Chronic Kidney Disease 2103 2Katie Lee Joel to Conduct Free Hands On Holiday Cooking Demonstration for Local Patients With Chronic Kidney Disease 2103 3Katie Lee Joel to Conduct Free Hands On Holiday Cooking Demonstration for Local Patients With Chronic Kidney Disease 2103 4Katie Lee Joel to Conduct Free Hands On Holiday Cooking Demonstration for Local Patients With Chronic Kidney Disease 2103 5Katie Lee Joel to Conduct Free Hands On Holiday Cooking Demonstration for Local Patients With Chronic Kidney Disease 2103 6Katie Lee Joel to Conduct Free Hands On Holiday Cooking Demonstration for Local Patients With Chronic Kidney Disease 2103 7Tutogen Medical Inc to Report Fourth Quarter and Fiscal Year 2007 Financial Results 2100 1Tutogen Medical Inc to Report Fourth Quarter and Fiscal Year 2007 Financial Results 2100 2
...007 – On 23 July SYGNIS Pharma,AG will prese...,AX200 (AXIS-study)., AX200, a compound for the tr...date in SYGNIS’ product pipeline. The,primar...ity of,AX200 in acute stroke patients. The results...tion for the further clinical,development of AX200...
...swire-FirstCall/ -- On Wednesday,July 11, 2007, a...entral European Time members of Cell Therapeutics,...ce call to discuss today,s,announcement of the int...ring CHOP-R to CPOP-R, in which pixantrone is subs...st-line treatment of patients,with aggressive non-...
Other Medicine Technology:Sygnis Pharma AG announces date for presentation of clinical,results 2Cell Therapeutics, Inc. Management to Discuss Today's Announcement,of Interim Pixantrone Study Results 2
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
Medicine Products: